Standout Papers

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the F... 2016 2026 2019 2022 334
  1. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial (2016)
    Séverine Vermeire, Stefan Schreiber et al. The Lancet

Immediate Impact

3 from Science/Nature 69 standout
Sub-graph 1 of 21

Citing Papers

Crohn's disease
2024 Standout
Navigating the complexities of drug development for inflammatory bowel disease
2024 Standout

Works of Adrian Goldiș being referenced

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
2016 Standout

Author Peers

Author Last Decade Papers Cites
Adrian Goldiș 448 344 181 35 737
Aysel Ülker 352 235 234 41 631
Wan‐Ju Lee 362 273 130 44 692
Roni Weisshof 532 361 183 30 763
Edyta Szymańska 532 356 220 55 777
Wee Chian Lim 444 337 219 28 797
Siro Bagnoli 378 306 188 36 763
Abbi R. Saniabadi 550 365 186 30 834
Jesse Siffledeen 490 428 160 27 776
Fukiko Komaki 339 320 220 33 757
Richard A. Lirio 611 488 237 30 795

All Works

Loading papers...

Rankless by CCL
2026